|
PHF3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.47940004691094E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.57299728797966E-11 |
| Normal-vs-Stage2 |
7.46499999593198E-08 |
| Normal-vs-Stage3 |
4.36090052957638E-10 |
| Normal-vs-Stage4 |
3.5953999777405E-09 |
| Stage1-vs-Stage2 |
3.783400E-01 |
| Stage1-vs-Stage3 |
1.040950E-01 |
| Stage1-vs-Stage4 |
2.574600E-01 |
| Stage2-vs-Stage3 |
7.716400E-01 |
| Stage2-vs-Stage4 |
8.614000E-01 |
| Stage3-vs-Stage4 |
9.141400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.78759995694833E-09 |
| Normal-vs-AfricanAmerican |
3.063400E-03 |
| Normal-vs-Asian |
3.38610000039097E-07 |
| Caucasian-vs-AfricanAmerican |
1.380400E-01 |
| Caucasian-vs-Asian |
6.832000E-01 |
| AfricanAmerican-vs-Asian |
3.072800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.5065000075486E-09 |
| Normal-vs-Female |
1.77624581709779E-12 |
| Male-vs-Female |
6.971200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.00469998987052E-09 |
| Normal-vs-Age(41-60Yrs) |
3.27793348020577E-12 |
| Normal-vs-Age(61-80Yrs) |
2.35999997322267E-10 |
| Normal-vs-Age(81-100Yrs) |
2.17030000004836E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.296600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.851600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.174000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.616200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.359600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.649200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.133580E-01 |
| Classical-VS-Follicular |
3.833200E-04 |
| Classical-VS-Other |
7.727200E-01 |
| Classical-VS-Normal |
2.12370000030049E-07 |
| Tall-VS-Follicular |
4.248600E-01 |
| Tall-VS-Other |
5.820000E-01 |
| Tall-VS-Normal |
3.16399999533701E-08 |
| Follicular-VS-Other |
4.079600E-01 |
| Follicular-VS-Normal |
7.01505520339651E-12 |
| Other-VS-Normal |
1.988470E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.73825448163734E-14 |
| Normal-vs-N1 |
3.37379999493237E-08 |
| N0-vs-N1 |
9.686000E-01 |
|
|
